A case of individualized therapy with delayed excretion of high-dose
This paper reports an elderly patient with central diffuse large B lymphoma who was given a high-dose methotrexate regimen after diagnosis.The concentration of methotrexate in the patient reached 47.25 μmol/L 24 h after chemotherapy,suggesting that the early excretion of methotrexate was delayed,while creatinine and uric acid were progressively increased.Clinical pharmacists played an active role in the selection of high-dose methotrexate infusion speed,rescue time,formulation of calcium folinate rescue plan,analysis of factors affecting methotrexate blood concentration,drug interaction,formulation of hydration,alkalization and other pretreatment plans,and pharmaceutical care,etc.The patient was finally discharged after a stable condition through the joint efforts of medical staff and clinical pharmacists.
high-dose methotrexatecentral diffuse large B lymphomadelayed excretionindividualized therapy
NETL
NSTL
万方数据
